Data Monitoring Committees issues

Current version

PDF iconDraft questions and answers

Deadline for comments: 31/07/2019

Reference numberEMA/492010/2018
Published01/08/2018
KeywordsData Monitoring Committee (DMC); clinical trial; study design; trial integrity; early drug development phase; safety review committee; competent regulatory authority
DescriptionThe aim of this question-and-answer document is to supplement the CHMP Data Monitoring Committee Guideline (Doc Ref. EMEA/CHMP/EWP/5872/03) by providing clarification on the role and necessity for a Data Monitoring Committee (DMC) in different phases of drug development and throughout the product lifecycle as well as with regard to the responsibilities for implementing DMC decisions.


Related content


How useful was this page?

Add your rating
Average
3 ratings